Fidelity Investments
PRME icon

Fidelity Investments’s Prime Medicine PRME Stock Holding History

Fidelity Investments’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.16M Sell
1,769,476
-407,170
-19% -$1.55M ﹤0.01% 2233
2025
Q4 		$7.55M Sell
2,176,646
-636,429
-23% -$2.83M ﹤0.01% 2138
2025
Q3 		$15.6M Sell
2,813,075
-931,352
-25% -$3.78M ﹤0.01% 1831
2025
Q2 		$9.25M Sell
3,744,427
-2,808
-0.1% -$4.33K ﹤0.01% 1962
2025
Q1 		$7.46M Sell
3,747,235
-54,793
-1% -$140K ﹤0.01% 2016
2024
Q4 		$11.1M Buy
3,802,028
+58,716
+2% +$206K ﹤0.01% 1905
2024
Q3 		$14.5M Sell
3,743,312
-184,541
-5% -$855K ﹤0.01% 1813
2024
Q2 		$20.2M Buy
3,927,853
+3,483
+0.1% +$21.1K ﹤0.01% 1649
2024
Q1 		$27.5M Sell
3,924,370
-976
-0% -$7.4K ﹤0.01% 1548
2023
Q4 		$34.8M Buy
3,925,346
+2,930
+0.1% +$22.6K ﹤0.01% 1430
2023
Q3 		$37.4M Sell
3,922,416
-116,803
-3% -$1.52M ﹤0.01% 1352
2023
Q2 		$59.2M Sell
4,039,219
-4,477,910
-53% -$62.5M 0.01% 1212
2023
Q1 		$105M Buy
8,517,129
+54,083
+0.6% +$881K 0.01% 967
2022
Q4 		$157M Buy
+8,463,046
New +$153M 0.02% 785

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Fidelity Investments's PRME Position: Q1 2026 in Review

Fidelity Investments reduced its Prime Medicine (PRME) stake by 19% in Q1 2026, selling an estimated $1.55M and leaving 1,769,476 shares worth $6.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2233.

Fidelity Investments first reported a position in PRME in Q4 2022 and has held it in 14 quarters since. The position peaked at $157M in Q4 2022. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Fidelity Investments held 1,769,476 shares of Prime Medicine worth $6.16M as of Q1 2026.
  • Fidelity Investments sold 407,170 Prime Medicine shares in Q1 2026, an estimated $1.55M.
  • Prime Medicine made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #2233 holding.
  • Fidelity Investments first reported a position in Prime Medicine in Q4 2022 and has held it in 14 quarters since.
  • Fidelity Investments's Prime Medicine position peaked at $157M in Q4 2022.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.